Kolon TissueGene, Inc. (KOSDAQ:950160)
45,000
-1,800 (-3.85%)
Oct 10, 2025, 3:30 PM KST
Kolon TissueGene Revenue
Kolon TissueGene had revenue of 1.34B KRW in the quarter ending June 30, 2025, with 40.13% growth. This brings the company's revenue in the last twelve months to 5.49B, up 16.53% year-over-year. In the year 2024, Kolon TissueGene had annual revenue of 5.07B with 36.90% growth.
Revenue (ttm)
5.49B
Revenue Growth
+16.53%
P/S Ratio
680.10
Revenue / Employee
189.40M
Employees
29
Market Cap
3,735.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.07B | 1.37B | 36.90% |
Dec 31, 2023 | 3.71B | -5.75B | -60.81% |
Dec 31, 2022 | 9.46B | 5.45B | 136.22% |
Dec 31, 2021 | 4.00B | 447.31M | 12.58% |
Dec 31, 2020 | 3.56B | 521.01M | 17.17% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
LigaChem Biosciences | 148.28B |